217 related articles for article (PubMed ID: 15655555)
1. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.
Prang N; Preithner S; Brischwein K; Göster P; Wöppel A; Müller J; Steiger C; Peters M; Baeuerle PA; da Silva AJ
Br J Cancer; 2005 Jan; 92(2):342-9. PubMed ID: 15655555
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells.
Xiang W; Wimberger P; Dreier T; Diebold J; Mayr D; Baeuerle PA; Kimmig R
J Cancer Res Clin Oncol; 2003 Jun; 129(6):341-8. PubMed ID: 12819960
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment.
Naundorf S; Preithner S; Mayer P; Lippold S; Wolf A; Hanakam F; Fichtner I; Kufer P; Raum T; Riethmüller G; Baeuerle PA; Dreier T
Int J Cancer; 2002 Jul; 100(1):101-10. PubMed ID: 12115595
[TBL] [Abstract][Full Text] [Related]
4. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
[TBL] [Abstract][Full Text] [Related]
6. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
Preithner S; Elm S; Lippold S; Locher M; Wolf A; da Silva AJ; Baeuerle PA; Prang NS
Mol Immunol; 2006 Mar; 43(8):1183-93. PubMed ID: 16102830
[TBL] [Abstract][Full Text] [Related]
7. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Richter CE; Cocco E; Bellone S; Silasi DA; Rüttinger D; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2010 Dec; 203(6):582.e1-7. PubMed ID: 20870202
[TBL] [Abstract][Full Text] [Related]
8. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model.
Lutterbuese P; Brischwein K; Hofmeister R; Crommer S; Lorenczewski G; Petersen L; Lippold S; da Silva A; Locher M; Baeuerle PA; Schlereth B
Cancer Immunol Immunother; 2007 Apr; 56(4):459-68. PubMed ID: 16937114
[TBL] [Abstract][Full Text] [Related]
9. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas.
Velders MP; van Rhijn CM; Oskam E; Fleuren GJ; Warnaar SO; Litvinov SV
Br J Cancer; 1998 Aug; 78(4):478-83. PubMed ID: 9716030
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
Barok M; Tanner M; Köninki K; Isola J
Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
12. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
Thurm H; Ebel S; Kentenich C; Hemsen A; Riethdorf S; Coith C; Wallwiener D; Braun S; Oberhoff C; Jänicke F; Pantel K
Clin Cancer Res; 2003 Jul; 9(7):2598-604. PubMed ID: 12855636
[TBL] [Abstract][Full Text] [Related]
13. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.
Kute TE; Savage L; Stehle JR; Kim-Shapiro JW; Blanks MJ; Wood J; Vaughn JP
Cancer Immunol Immunother; 2009 Nov; 58(11):1887-96. PubMed ID: 19340424
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
[TBL] [Abstract][Full Text] [Related]
15. Preparation of human IgG and IgM monoclonal antibodies for MK-1/Ep-CAM by using human immunoglobulin gene-transferred mouse and gene cloning of their variable regions.
Kuroki M; Yamada H; Shibaguchi H; Hachimine K; Hirose Y; Kinugasa T; Ishida I; Kuroki M
Anticancer Res; 2005; 25(6A):3733-9. PubMed ID: 16302733
[TBL] [Abstract][Full Text] [Related]
16. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
[TBL] [Abstract][Full Text] [Related]
17. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
[TBL] [Abstract][Full Text] [Related]
18. Specific targeting of Ep-CAM in various carcinomas by novel monoclonal antibodies.
Sithambaram D; Palanivelu S; Subramanian K; Sahoo S; Verma RS
Hybridoma (Larchmt); 2011 Dec; 30(6):511-8. PubMed ID: 22149275
[TBL] [Abstract][Full Text] [Related]
19. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.
Köninki K; Barok M; Tanner M; Staff S; Pitkänen J; Hemmilä P; Ilvesaro J; Isola J
Cancer Lett; 2010 Aug; 294(2):211-9. PubMed ID: 20193978
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
